Meningococcal vaccines are now available that help protect against all three serogroups of meningococcal disease that are most commonly observed (serogroups B, C and Y), but they do not prevent all the cases. Meningococcal disease is a contagious and life threatening infection of the meninges (connective tissue surrounding the brain and spinal cord). The disease occurs worldwide with considerable geographic variability in serogroup distribution. It has the highest incidence in young children regardless of serogroup type. Currently, none of the vaccines available provide protection against all serogroups causing meningococcal disease, although there are vaccines covering a broad range of serogroups. There are three kinds of meningococcal vaccines available: Meningococcal combination vaccines (Bexsero, Trumenba, MenHibrix, Menitorix); Meningococcal conjugate vaccines (Menactra, MenAfriVac, Meningitec, Menjugate, Menveo, NeisVac-C, Nimenrix, NmVac4-DT); Meningococcal polysaccharide vaccine (Bi Meningo, Mencevax, Menomune, NmVac4, Quadri Meningo).
The global meningococcal vaccines market report estimates the market size (Revenue US$ million – 2014 to 2021) based on combination vaccines, conjugate vaccines and polysaccharide vaccine and also forecasts growth trends (CAGR% – 2017 to 2021).
The global meningococcal vaccines market report also provides the detailed market landscape, market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments. The global meningococcal vaccines market research report is divided by geography (regional and country based) into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World.
Major players operating in the global meningococcal vaccines market and included in this report are Baxter International, Biomed Pvt. Ltd., GlaxoSmithKline plc, JN International Medical Corporation, Nuron Biotech, Novartis International AG, Pfizer, Inc., Serum Institute of India, Ltd., and Sanofi S.A.